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Non-small cell lung cancer (NSCLC) comprises about 84% of all lung cancers. Many
treatment options are available but the survival rate is still very low due to drug
resistance. It has been found that phosphoinositide-3-kinase (PI3K) affects sensitivity
to tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib. Expression level of
seven in absentia homolog 2 (SIAH2), an E3 ubiquitin-protein ligase, is upregulated in
NSCLC and correlated with tumor grade. However, the relationship between PI3K and
SIAH2 remains unclear and therefore it is not known whether they can act as treatment
co-targets and theranostic dual markers for overcoming TKI resistance. It is worthy to
note that PI3K and SIAH2 are potentially regulated by a common group of microRNAs
in miR-30 family. Our bioinformatics analyses showed upregulated SIAH2 expression
in NSCLC based on mass spectrometry data, explored its indirect interaction with
PI3K and predicted their targeting microRNAs in common. We have also explored the
potential role of miR-30 family in the modulation of PI3K-SIAH2 interaction in NSCLC.
Keywords: PI3K, SIAH2, non-small cell lung cancer, theranostics, microRNA
INTRODUCTION
Every year, about 1.8 million new lung cancer cases are diagnosed, claiming 1.6 million deaths
globally. Non-small cell lung cancer (NSCLC) is a major form of lung cancer, comprising
approximately 84% of all lung cancers. Although many treatment options, including targeted
therapy, are available, the survival rate is still very low because of ineffective treatment outcome
and acquired drug resistance. In Hong Kong, the survival rate of NSCLC is about 15% only (Ho,
2011). Although cigarette smoking has predominant association with lung cancer, non-smokers
constitute a substantial minority of lung cancer patients. In the USA, 17,000–26,000 annual deaths
of non-smokers from lung cancer account for the seventh leading cause of cancer mortality (Rivera
and Wakelee, 2016). With the exposure to passive smoke and cooking fumes, non-smoking women
represent an under-studied subset of NSCLC patients (Shen et al., 1998).
The current therapeutic approaches mainly target the molecular mechanisms of tumor cell
growth caused by the aberrant activity of epidermal growth factor receptor (EGFR) (Camp et al.,
2005). EGFR tyrosine kinase inhibitors (TKIs) are small molecules designed to bind to the tyrosine
kinase domain of EGFR so that its phosphorylation and the subsequent receptor activation
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and signal transduction can be inhibited. However, the cancer
progression remains because of the acquired resistance to
EGFR TKIs (Yu et al., 2013). To date, no effective therapy
is available for NSCLC patients with such resistance. Multiple
molecular mechanisms of resistance have been explored, such
as the activation of alternative receptor tyrosine kinases (RTKs)
that bypass the EGFR signaling pathway, and the secondary
mutations in EGFR T790M (Camp et al., 2005; Zhang et al.,
2012). The resistance to anti-EGFR therapy may be caused
by the activation of other RTKs, such as hepatocyte growth
factor receptor (c-MET), Ron (a protein tyrosine kinase related
to c-MET), platelet-derived growth factor receptor (PDGFR),
and insulin-like growth factor receptor-1 (IGF-1R), which
share the same downstream signaling cascade with EGFR
pathway (Camp et al., 2005). The other activated RTKs
are able to substitute the function of EGFR by activating
overlapping signal transduction. The downstream molecule
phosphoinositide-3-kinase (PI3K) shared by both EGFR and
IGF-1R is associated with the EGFR TKIs resistance (Huang and
Fu, 2015).
PI3K Signaling Cascade Coupled with
RTKs
Upon ligand binding, RTKs dimerize and phosphorylate each
other. The adaptor proteins recruit the p85 regulatory subunit
of Class IA PI3K heterodimer, which is expressed by PIK3R1,
PIK3R2, PIK3R3, p85β, and p55γ, to the phosphorylated
cytosolic RTK domains. The recruitment of p85 subunit
results in a conformational change in the PI3K heterodimer
that activates its p110 catalytic subunit, phosphorylates
phosphatidylinositol 4,5-bisphosphate (PIP2) and converts
PIP2 to phosphatidylinositol (3,4,5)-trisphosphate (PIP3).
Protein kinase B (AKT) is then recruited by PIP3 to the cell
membrane where the conserved serine residue of AKT is
phosphorylated by TORC2. The phosphorylated AKT interact
with a number of proteins participating in cell survival and
metabolism (Manning et al., 2002).
Casitas B-lineage lymphoma (CBL) and PI3K are both
downstream proteins of EGFR. CBL is an E3 ubiquitin ligase
consisting of tyrosine kinase binding (TKB), RING finger
domain and ubiquitin-associated domains. PI3K-phosphorylated
protein activates TKB domain at the N-terminal of CBL
and stimulates its ubiquitination activity. With response to
this signal, RING finger domain recruits an E2 ubiquitin-
conjugating enzyme, such as UBE2D2, and ubiquitin-associated
domain transfers ubiquitin from the enzyme to targeted
substrates for degradation. Such process may promote the
ubiquitination of RTK by degradation and attenuates RTK signal
transduction.
SIAH2 in EGFR Pathway
The seven in absentia homolog 2 (SIAH2) is another E3
ubiquitin ligase that also mediates ubiquitination and
subsequent proteasomal degradation of target proteins. In
addition to AKT and PI3K, p38 mitogen-activated protein
kinase (MAPK) are the downstream proteins of EGFR
pathway. Major phosphorylation sites of SIAH2, S29, and
T24, contains the SQ/TQ amino acid sequence motif, which
is conserved for p38 MAPK phosphorylation. Hypoxia is
a condition that promotes the activities of both SIAH2
and p38 MAPK (Nakayama et al., 2009). Under hypoxic
condition, p38 MAPK actively phosphorylates and stabilizes
SIAH2 in cytoplasm (Emerling et al., 2005; Khurana et al.,
2006). However, the role of SIAH2 in NSCLC remains
unclear.
Post-transcriptional Regulation by
MicroRNAs
MicroRNAs (miRNAs) represent a class of endogenous and
non-coding RNAs whose mature forms are short fragments
of 21–25 nucleotides long. To post-transcriptionally regulate
the expression of their target genes, miRNAs bind to the
miRNA response elements (MREs) of their messenger RNAs
(mRNAs). MREs are the sequence motifs in 3′-untranslated
region (3′-UTR) of mRNAs complementary to the targeting
miRNAs. MiRNAs are not only able to regulate the expression
of the target oncogenes or tumor suppressor genes in human
tumors, but also to alter the acquired drug resistance and
tumor progression so that the treatment response to targeted
therapy is improved particularly in NSCLC (Medina and Slack,
2008; Weiss et al., 2008; Han et al., 2015; Yu and Cho,
2015; Sin et al., 2016). It was reported that the gefitinib-
induced apoptosis and epithelial-mesenchymal transition of
NSCLC cells were affected by miR-30b and miR-30c through the
inhibition of some oncogenes, such as sarcoma viral oncogene
homolog (SRC) (Skog et al., 2008). As a miRNA able to
target multiple genes, it is interesting to examine whether
miR-30 family plays a theranostic role in regulating PI3K and
SIAH2 concurrently and mediating the potential PI3K–SIAH2
interaction in NSCLC.
FIGURE 1 | Interactions among PI3K, CBL, UBE2D2, SIAH2, and
miR-30-5p. Grb2: growth factor receptor-binding protein 2; GAB1:
GRB2-associated-binding protein 1.
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MATERIALS AND METHODS
Proteomic Analysis of Blood Samples
The plasma samples of this study were archived specimens.
Among 105 patients randomly selected from pretreatment
patients of Queen Elizabeth Hospital in Hong Kong,
plasma samples were collected from 60 non-cancer patients
and 45 adenocarcinoma patients. The non-cancer group
includes 30 lung disease patients without known neoplastic
tumor and 30 healthy volunteers free of any known acute
or chronic illness. The adenocarcinoma group consists
of 45 female nonsmokers (Eskandar et al., 2015). The
plasma samples was fractionated and then profiled with
the surface-enhanced laser desorption/ionization time-of-
flight mass spectrometer (SELDI-TOF-MS), we analyzed
the array on a Proteinchip PCS4000 Reader (Ciphergen
Biosystems) with acquisition up to 200 kDa and generated
the m/z spectra by averaging a total of 338 laser shots
at an intensity of 195. The proteomic profile data from
fractionation with pH 9 with cationic CM10 chip was used in this
study.
Peptide Prediction and Differential
Expression Analysis
The molecular mass of SIAH2 is 34.615 kDa. It was predicted
by Mascot MS/MS Ions Search (Matrix Science1) that a peptide
with mass of 34461.667 Da could constitute 2–324 residues
of SIAH2 and correspond to the m/z ratio 17230.8335 Da in
the generated mass spectra. At this m/z ratio, we compared
the intensity values of the adenocarcinoma group with that of
the non-cancer group using independent sample t-test or its
non-parameter counterpart depending on the normality of data.
Differential expression of SIAH2 was indicated by p< 0.05 in the
statistical test.
Protein–Protein Interaction Search
We used Search Tool for Recurring Instances of Neighbouring
Genes (STRING) to identify the potential interactions among
PI3K, CBL, UBE2D2, and SIAH2. STRING hosts the information
and corresponding evidence support of known and predicted
protein–protein interactions in database and serves query
functions and result visualizations. The interactions covered
by STRING are not only experimentally-proved direct physical
1http://www.matrixscience.com/
associations but also phylogenetic, genomic, or functional
indirect associations. Evidence of identified interactions is
supported by other primary databases, such as General
Repository for Interaction Datasets (GRID). As of September
2016, STRING database includes the interaction information
about 9,643,763 proteins from 2,031 organisms (Franceschini
et al., 2013).
MiRNA Target Prediction
TargetScan was used to predict the miRNAs that concurrently
regulate PI3K, CBL, UBE2D2, and SIAH2. In the prediction
process, TargetScan searched for the miRNAs whose seed regions
match the conserved 8-mer, 7-mer, and 6-mer sites of the target
genes’ mRNAs (Lewis et al., 2005). We did not limit the broadly
conserved, conserved, and poorly conserved but confidently
annotated microRNA families and included no other microRNA
annotations in our search.
RESULTS
For testing the normality of data, Shapiro–Wilk test was
performed to SELDI-TOF-MS intensity data of both non-
cancer and adenocarcinoma groups. Normality cannot be
assumed in non-cancer group (p < 0.0001) and adenocarcinoma
group (p = 0.001). So, the difference between two groups
was examined using non-parametric test, independent
samples Mann–Whitney U test. It was found that the
intensities of m/z = 17230.8335 Da were significantly
different between two groups (p = 0.002, median in non-
cancer = 0.1898, median in adenocarcinoma = 0.3075,
see Supplementary Materials). This implies that the
protein expression of SIAH2 is significantly upregulated in
adenocarcinoma.
Search Tool for Recurring Instances of Neighbouring
Genes predicted the interactions among PI3K, CBL,
UBE2D2, and SIAH2 (Figure 1). All the interactions were
supported by experimental results and co-mentioning
in literature. The CBL-UBE2D2 interaction was further
supported by the pathways curated from third-party
databases, such as Kyoto Encyclopedia of Genes and
Genomes (KEGG). Datasets relevant to these interactions
are shown in Table 1. Although there was no evidence
showing that PIK3R2 directly interact with SIAH2, TargetScan
predicted that miR-30-5p family concurrently targets
TABLE 1 | Protein–protein interactions detected by assays and the corresponding hosting databases.
Protein 1 Protein 2 Database Detected by
PIK3R2 CBL Intact Anti tag coimmunoprecipitation assay (psi-mi: “MI:0007”), tandem affinity purification assay
(psi-mi: “MI:0676”), anti bait coimmunoprecipitation assay (psi-mi: “MI:0006”)
PIK3R2 CBL Intact, pride Cross-linking assay (psi-mi: “MI:0030”)
PIK3R2 CBL GRID Affinity capture-western assay, affinity capture-MS assay
CBL UBE2D2 dip Surface plasmon resonance and X-ray crystallography assays
CBL UBE2D2 GRID Reconstituted complex assay
UBE2D2 SIAH2 GRID Reconstituted complex assay
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them. The involved members of miR-30-5p family include miR-
30a-5p, miR-30b-5p, miR-30c-5p, miR-30d-5p, and miR-30e-
5p. The type of pairing site between PIK3R2 and miR-30-5p
family members is 8mer and the target site is conserved among
mammals. The type of pairing site between SIAH2 and miR-30-
5p family members is 7mer-A1 and the target site is conserved
among a number of vertebrates. It is interesting to note that
miR-30-5p family also targets UBE2D2.
DISCUSSION AND CONCLUSION
This work investigated the roles of PIK3R2, CBL, UBE2D2,
SIAH2, and miR-30-5p family that may be related to the
resistance to anti-EGFR therapy. Among these factors, SIAH2
has not been studied sufficiently and its role in cancer
treatment remains unclear. In the comparison between plasma
samples of independent groups, we showed the significant
upregulation of SIAH2 protein in NSCLC. Moreno et al. (2015)
obtained similar result but the SIAH2 expression in lung
cancer was compared with that in adjacent normal tissues. Sun
et al. (2016) found that SIAH2 was overexpressed in human
breast cancer tissues. Our finding suggests that SIAH2 may
be a novel theranostic target in the circulation of NSCLC
patients.
Protein–protein interaction database search revealed the
experimental proofs using the reconstituted complex assays that
the E2 ubiquitin-conjugating enzyme, UBE2D2, interacts with
both CBL and SIAH2, E3 ubiquitin ligases. CBL ubiquitylates
active RTKs for degradation and attenuates directly the receptor
signaling, including that mediated by EGFR (Joazeiro et al.,
1999). The potential theranostic role of CBL has been shown
in Klapper et al. (2000) that some antibodies may enhance
directing HER-2 to CBL-regulated proteolysis. Similar to CBL,
SIAH2 ubiquitylates protein for degradation. However, there is
no evidence at the moment showing that the ubiquitination
of EGFR is related to SIAH2. On the other hand, it was
shown in Szargel et al. (2009) that SIAH2 is responsible
for the ubiquitination of alpha-synuclein and synphilin-1
in Lewy bodies of PD patients. The only association with
EGFR pathway is that both SIAH2 and MAPK are sensitive
to hypoxia and MAPK, a downstream protein of EGFR
can activate SIAH2 by phosphorylation (Nakayama et al.,
2009).
TargetScan predicted that mRNAs of PIK3R2, UBE2D2, and
SIAH2 are concurrently targeted by miRNA-30-5p family. These
three RNA transcripts sharing the same conserved MREs are
called competing endogenous RNA (ceRNA). CeRNAs interact
indirectly by competing for their common targeting miRNAs in
cells. The up-regulation of a ceRNA could indirectly promote
the expression of the other ceRNAs (Marques et al., 2011).
The molecular mechanism, through which the ceRNAs are co-
regulated, paves the undiscovered cascades in the signaling
pathway. Such co-regulation can be detected by the co-expression
of ceRNAs. It was shown that PTEN and its putative ceRNAs
are co-expressed in prostate cancer and glioblastoma (Tay et al.,
2011). The ceRNA crosstalk is susceptible to the miRNA:target
concentration ratio and, in other words, mediated by the
targeting miRNAs (Bosson et al., 2014).
Among the miRNA-30-5p family members, microRNA-
30a expression was found negatively associated with the
malignant potential of various NSCLC cell lines, positively
with the expression of E-cadherin, which is an epithelial
marker, and negatively with the expression of N-cadherin,
which is a mesenchymal marker. In other words, the epithelial-
to-mesenchymal transition could be inhibited by miR-30a
(Kumarswamy et al., 2012). Based on the above evidence,
interaction of PIK3R2-SIAH2 ceRNAs and its mediator, miRNA-
30-5p family, can be considered as a potential treatment target
and theranostic panel in NSCLC, particularly adenocarcinoma.
The treatment effect can be examined by intravenous injection
of Lipofectamine reagents of miRNA-30-5p inhibitor/mimic in
xenograft model and clinical trials.
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